Table 2.
Pooled SIRs of second HAC after primary tumours, and basal incidence, Europe and North America
| Primary cancer | Secondary cancer, pooled SIR (95% CI) | |||
|---|---|---|---|---|
| Cervix | Vulvo-vaginal | Anal | Oropharyngeal | |
| Cervix | 1.61 (0.39−6.65) | 7.76 (5.50−10.95) | 3.82 (2.35−6.20) | 1.72 (1.36−2.19) |
| CIN | 2.40 (2.15−2.68) | 5.09 (3.85−6.73) | 4.47 (2.66−7.51) | 2.01 (1.41−2.88) |
| Vulvo-vaginal | 5.95 (1.39−25.47) | 9.08 (5.46−15.12) | 13.69 (8.56−21.89) | 4.65 (2.36−9.16) |
| Anal | 1.75 (0.66−4.67) | 9.13 (5.84−14.28) | 30.81 (23.50−40.39) | 4.87 (1.96−6.81) |
| Penile | NA | NA | — | 3.88 (2.21−6.81) |
| Oropharyngeal | 2.21 (1.33−3.66) | 3.74 (1.72−8.15) | 2.70 (1.17−6.23) | 22.45 (12.70−39.68) |
| Incidence (UK) | 10 per 100,000 | 4.1 per 100,000 | 2 per 100,000 | 3−5 per 100,000 |
| Incidence (Europe)75 | 15.2 per 100,000 | 0.8−4.1 per 100,000 | 1.2 per 100,000 | 7.9 per 100,000 |
| Incidence (North America)75 | 8.1 per 100,000 | 2.5 per 100,000 | 1.8 per 100,000 | 6.1 per 100,000 |